Loading…
Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment
Cannabidiol (CBD), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (AEDs) in the treatment of refractory epilepsy (RE), decreasing the severity and/or frequency of seizures. CBD is considered a multitarget drug that could act throughout...
Saved in:
Published in: | Pharmaceuticals (Basel, Switzerland) Switzerland), 2021-03, Vol.14 (3), p.220 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23 |
---|---|
cites | cdi_FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23 |
container_end_page | |
container_issue | 3 |
container_start_page | 220 |
container_title | Pharmaceuticals (Basel, Switzerland) |
container_volume | 14 |
creator | Gómez, Claudia Taborda Lairion, Fabiana Repetto, Marisa Ettcheto, Miren Merelli, Amalia Lazarowski, Alberto Auzmendi, Jerónimo |
description | Cannabidiol (CBD), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (AEDs) in the treatment of refractory epilepsy (RE), decreasing the severity and/or frequency of seizures. CBD is considered a multitarget drug that could act throughout the canonical endocannabinoid receptors (CB1-CB2) or multiple non-canonical pathways. Despite the fact that the CBD mechanism in RE is still unknown, experiments carried out in our laboratory showed that CBD has an inhibitory role on P-glycoprotein excretory function, highly related to RE. Since CB2 is expressed mainly in the immune cells, we hypothesized that CBD treatment could alter the activity of polymorphonuclear neutrophils (PMNs) in a similar way that it does with microglia/macrophages and others circulating leukocytes. In vitro, CBD induced PMN cytoplasmatic vacuolization and proapoptotic nuclear condensation, associated with a significantly decreased viability in a concentration-dependent manner, while low CBD concentration decreased PMN viability in a time-dependent manner. At a functional level, CBD reduced the chemotaxis and oxygen consumption of PMNs related with superoxide anion production, while the singlet oxygen level was increased suggesting oxidative stress damage. These results are in line with the well-known CBD anti-inflammatory effect and support a potential immunosuppressor role on PMNs that could promote an eventual defenseless state during chronic treatment with CBD in RE. |
doi_str_mv | 10.3390/ph14030220 |
format | article |
fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0cc6bade296245839575415fc53071f6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_0cc6bade296245839575415fc53071f6</doaj_id><sourcerecordid>33807975</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23</originalsourceid><addsrcrecordid>eNpVkVtPGzEQhS3Uqlzal_6Ayo-AFOrLeL1-qUQDoZEoRQieLa_XS4yc9cp2KuXfsyRcn2Y0c843Gh2EvlNywrkiP4cFBcIJY2QH7VFgMKkZyE_v-l20n_MDIUJSoF_QLuc1kUqKPZSmpu9N41sfAz6c_j47wqehuJRxWTg8W_W2-Nib4Msaxw5fuVVJcVj4kPHh9d-roxM8Xw7BW_Mky9j3G9-N65KxJaY1Ph98cENe49vkTFm6vnxFnzsTsvv2XA_Q3ez8dvpncvnvYj49vZxYACgTAwQqIW0r60pC52rqOJMd1EJKEJwyaZRSwFvRqLYZVRRMQ7gc3Yo3LeMHaL7lttE86CH5pUlrHY3Xm0FM99qk4m1wmlhbNaZ1TFUMRM2VkAKo6KzgRNKuGlm_tqxh1Sxda8c3kgkfoB83vV_o-_hf14RQQeoRcLwF2BRzTq579VKin1LUbymO4h_vr71KX2Ljj7b1l1E</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Gómez, Claudia Taborda ; Lairion, Fabiana ; Repetto, Marisa ; Ettcheto, Miren ; Merelli, Amalia ; Lazarowski, Alberto ; Auzmendi, Jerónimo</creator><creatorcontrib>Gómez, Claudia Taborda ; Lairion, Fabiana ; Repetto, Marisa ; Ettcheto, Miren ; Merelli, Amalia ; Lazarowski, Alberto ; Auzmendi, Jerónimo</creatorcontrib><description>Cannabidiol (CBD), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (AEDs) in the treatment of refractory epilepsy (RE), decreasing the severity and/or frequency of seizures. CBD is considered a multitarget drug that could act throughout the canonical endocannabinoid receptors (CB1-CB2) or multiple non-canonical pathways. Despite the fact that the CBD mechanism in RE is still unknown, experiments carried out in our laboratory showed that CBD has an inhibitory role on P-glycoprotein excretory function, highly related to RE. Since CB2 is expressed mainly in the immune cells, we hypothesized that CBD treatment could alter the activity of polymorphonuclear neutrophils (PMNs) in a similar way that it does with microglia/macrophages and others circulating leukocytes. In vitro, CBD induced PMN cytoplasmatic vacuolization and proapoptotic nuclear condensation, associated with a significantly decreased viability in a concentration-dependent manner, while low CBD concentration decreased PMN viability in a time-dependent manner. At a functional level, CBD reduced the chemotaxis and oxygen consumption of PMNs related with superoxide anion production, while the singlet oxygen level was increased suggesting oxidative stress damage. These results are in line with the well-known CBD anti-inflammatory effect and support a potential immunosuppressor role on PMNs that could promote an eventual defenseless state during chronic treatment with CBD in RE.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph14030220</identifier><identifier>PMID: 33807975</identifier><language>eng</language><publisher>Switzerland: MDPI</publisher><subject>cannabidiol ; chemotaxis ; oxidative stress ; oxygen consumption ; polymorphonuclear neutrophils (PMNs) ; refractory epilepsy</subject><ispartof>Pharmaceuticals (Basel, Switzerland), 2021-03, Vol.14 (3), p.220</ispartof><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23</citedby><cites>FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23</cites><orcidid>0000-0001-8979-7631 ; 0000-0002-4301-7297</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001508/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001508/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33807975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez, Claudia Taborda</creatorcontrib><creatorcontrib>Lairion, Fabiana</creatorcontrib><creatorcontrib>Repetto, Marisa</creatorcontrib><creatorcontrib>Ettcheto, Miren</creatorcontrib><creatorcontrib>Merelli, Amalia</creatorcontrib><creatorcontrib>Lazarowski, Alberto</creatorcontrib><creatorcontrib>Auzmendi, Jerónimo</creatorcontrib><title>Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment</title><title>Pharmaceuticals (Basel, Switzerland)</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>Cannabidiol (CBD), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (AEDs) in the treatment of refractory epilepsy (RE), decreasing the severity and/or frequency of seizures. CBD is considered a multitarget drug that could act throughout the canonical endocannabinoid receptors (CB1-CB2) or multiple non-canonical pathways. Despite the fact that the CBD mechanism in RE is still unknown, experiments carried out in our laboratory showed that CBD has an inhibitory role on P-glycoprotein excretory function, highly related to RE. Since CB2 is expressed mainly in the immune cells, we hypothesized that CBD treatment could alter the activity of polymorphonuclear neutrophils (PMNs) in a similar way that it does with microglia/macrophages and others circulating leukocytes. In vitro, CBD induced PMN cytoplasmatic vacuolization and proapoptotic nuclear condensation, associated with a significantly decreased viability in a concentration-dependent manner, while low CBD concentration decreased PMN viability in a time-dependent manner. At a functional level, CBD reduced the chemotaxis and oxygen consumption of PMNs related with superoxide anion production, while the singlet oxygen level was increased suggesting oxidative stress damage. These results are in line with the well-known CBD anti-inflammatory effect and support a potential immunosuppressor role on PMNs that could promote an eventual defenseless state during chronic treatment with CBD in RE.</description><subject>cannabidiol</subject><subject>chemotaxis</subject><subject>oxidative stress</subject><subject>oxygen consumption</subject><subject>polymorphonuclear neutrophils (PMNs)</subject><subject>refractory epilepsy</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkVtPGzEQhS3Uqlzal_6Ayo-AFOrLeL1-qUQDoZEoRQieLa_XS4yc9cp2KuXfsyRcn2Y0c843Gh2EvlNywrkiP4cFBcIJY2QH7VFgMKkZyE_v-l20n_MDIUJSoF_QLuc1kUqKPZSmpu9N41sfAz6c_j47wqehuJRxWTg8W_W2-Nib4Msaxw5fuVVJcVj4kPHh9d-roxM8Xw7BW_Mky9j3G9-N65KxJaY1Ph98cENe49vkTFm6vnxFnzsTsvv2XA_Q3ez8dvpncvnvYj49vZxYACgTAwQqIW0r60pC52rqOJMd1EJKEJwyaZRSwFvRqLYZVRRMQ7gc3Yo3LeMHaL7lttE86CH5pUlrHY3Xm0FM99qk4m1wmlhbNaZ1TFUMRM2VkAKo6KzgRNKuGlm_tqxh1Sxda8c3kgkfoB83vV_o-_hf14RQQeoRcLwF2BRzTq579VKin1LUbymO4h_vr71KX2Ljj7b1l1E</recordid><startdate>20210305</startdate><enddate>20210305</enddate><creator>Gómez, Claudia Taborda</creator><creator>Lairion, Fabiana</creator><creator>Repetto, Marisa</creator><creator>Ettcheto, Miren</creator><creator>Merelli, Amalia</creator><creator>Lazarowski, Alberto</creator><creator>Auzmendi, Jerónimo</creator><general>MDPI</general><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8979-7631</orcidid><orcidid>https://orcid.org/0000-0002-4301-7297</orcidid></search><sort><creationdate>20210305</creationdate><title>Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment</title><author>Gómez, Claudia Taborda ; Lairion, Fabiana ; Repetto, Marisa ; Ettcheto, Miren ; Merelli, Amalia ; Lazarowski, Alberto ; Auzmendi, Jerónimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>cannabidiol</topic><topic>chemotaxis</topic><topic>oxidative stress</topic><topic>oxygen consumption</topic><topic>polymorphonuclear neutrophils (PMNs)</topic><topic>refractory epilepsy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez, Claudia Taborda</creatorcontrib><creatorcontrib>Lairion, Fabiana</creatorcontrib><creatorcontrib>Repetto, Marisa</creatorcontrib><creatorcontrib>Ettcheto, Miren</creatorcontrib><creatorcontrib>Merelli, Amalia</creatorcontrib><creatorcontrib>Lazarowski, Alberto</creatorcontrib><creatorcontrib>Auzmendi, Jerónimo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez, Claudia Taborda</au><au>Lairion, Fabiana</au><au>Repetto, Marisa</au><au>Ettcheto, Miren</au><au>Merelli, Amalia</au><au>Lazarowski, Alberto</au><au>Auzmendi, Jerónimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2021-03-05</date><risdate>2021</risdate><volume>14</volume><issue>3</issue><spage>220</spage><pages>220-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>Cannabidiol (CBD), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (AEDs) in the treatment of refractory epilepsy (RE), decreasing the severity and/or frequency of seizures. CBD is considered a multitarget drug that could act throughout the canonical endocannabinoid receptors (CB1-CB2) or multiple non-canonical pathways. Despite the fact that the CBD mechanism in RE is still unknown, experiments carried out in our laboratory showed that CBD has an inhibitory role on P-glycoprotein excretory function, highly related to RE. Since CB2 is expressed mainly in the immune cells, we hypothesized that CBD treatment could alter the activity of polymorphonuclear neutrophils (PMNs) in a similar way that it does with microglia/macrophages and others circulating leukocytes. In vitro, CBD induced PMN cytoplasmatic vacuolization and proapoptotic nuclear condensation, associated with a significantly decreased viability in a concentration-dependent manner, while low CBD concentration decreased PMN viability in a time-dependent manner. At a functional level, CBD reduced the chemotaxis and oxygen consumption of PMNs related with superoxide anion production, while the singlet oxygen level was increased suggesting oxidative stress damage. These results are in line with the well-known CBD anti-inflammatory effect and support a potential immunosuppressor role on PMNs that could promote an eventual defenseless state during chronic treatment with CBD in RE.</abstract><cop>Switzerland</cop><pub>MDPI</pub><pmid>33807975</pmid><doi>10.3390/ph14030220</doi><orcidid>https://orcid.org/0000-0001-8979-7631</orcidid><orcidid>https://orcid.org/0000-0002-4301-7297</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1424-8247 |
ispartof | Pharmaceuticals (Basel, Switzerland), 2021-03, Vol.14 (3), p.220 |
issn | 1424-8247 1424-8247 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_0cc6bade296245839575415fc53071f6 |
source | Open Access: PubMed Central; Publicly Available Content (ProQuest) |
subjects | cannabidiol chemotaxis oxidative stress oxygen consumption polymorphonuclear neutrophils (PMNs) refractory epilepsy |
title | Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T02%3A16%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cannabidiol%20(CBD)%20Alters%20the%20Functionality%20of%20Neutrophils%20(PMN).%20Implications%20in%20the%20Refractory%20Epilepsy%20Treatment&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=G%C3%B3mez,%20Claudia%20Taborda&rft.date=2021-03-05&rft.volume=14&rft.issue=3&rft.spage=220&rft.pages=220-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph14030220&rft_dat=%3Cpubmed_doaj_%3E33807975%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c444t-a404657cd78674fe81e327f48577453127a99943d5b9dbd7814ab037c4493bd23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33807975&rfr_iscdi=true |